Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormone-refractory Prostate Cancer.

Brian I Rini1, Eric J Small

  • 1University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Avenue, 3rd Floor, 94115, USA. brini@medicine.ucsf.edu

Current Treatment Options in Oncology
|August 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026
Same author

Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.

Oncology and therapy·2026
Same author

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

European urology·2026
Same author

Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

The oncologist·2026
Same author

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026
Same author

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Nature reviews. Clinical oncology·2026
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Advanced prostate cancer treatments are evolving. New therapies, including secondary hormonal manipulation and chemotherapy, offer hope for patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation failure.

Area of Science:

  • Oncology
  • Urology
  • Medical Research

Background:

  • Androgen deprivation therapy (ADT) has been the standard for advanced prostate cancer for over 50 years.
  • Resistance to ADT inevitably develops, leading to hormone-refractory prostate cancer (HRPC).
  • HRPC was historically considered difficult to treat, with limited options.

Purpose of the Study:

  • To explore new therapeutic strategies for advanced prostate cancer.
  • To investigate the efficacy of secondary hormonal manipulation in HRPC.
  • To evaluate the role of chemotherapy in managing HRPC.

Main Methods:

  • Review of current treatment paradigms for advanced prostate cancer.
  • Analysis of emerging treatment options for HRPC.
  • Discussion of the heterogeneity of HRPC and its implications for treatment.

Related Experiment Videos

Main Results:

  • Secondary hormonal manipulation can be effective in some HRPC patients.
  • Chemotherapeutic regimens provide viable treatment options for HRPC.
  • HRPC is a heterogeneous disease, necessitating tailored treatment approaches.

Conclusions:

  • The treatment landscape for HRPC has significantly improved with new therapeutics.
  • Secondary hormonal manipulation and chemotherapy represent key advancements in HRPC management.
  • Recognizing HRPC heterogeneity is crucial for successful treatment strategies.